Pharmacyclics Price Target Raised to $111.00 at Goldman Sachs Group Inc. (PCYC)
Investment analysts at Goldman Sachs Group Inc. boosted their price target on shares of Pharmacyclics (NASDAQ:PCYC) from $102.00 to $111.00 in a note issued to investors on Wednesday, Stock Ratings Network.com reports. Goldman Sachs Group Inc.’s price target suggests a potential downside of 9.43% from the stock’s previous close.
Pharmacyclics (NASDAQ:PCYC) traded up 2.26% during mid-day trading on Wednesday, hitting $122.552. The stock had a trading volume of 444,833 shares. Pharmacyclics has a 52 week low of $44.91 and a 52 week high of $122.86. The stock’s 50-day moving average is $114.1 and its 200-day moving average is $93.23. The company has a market cap of $8.964 billion and a P/E ratio of 116.58.
Pharmacyclics (NASDAQ:PCYC) last posted its quarterly earnings results on Wednesday, July 31st. The company reported $0.26 EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.07) by $0.33. The company had revenue of $54.70 million for the quarter, compared to the consensus estimate of $52.00 million. On average, analysts predict that Pharmacyclics will post $-0.30 earnings per share for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at Lazard Capital Markets upgraded shares of Pharmacyclics (NASDAQ:PCYC) from a “neutral” rating to a “buy” rating in a research note to investors on Wednesday, September 4th. They now have a $141.00 price target on the stock. Separately, analysts at Roth Capital raised their price target on shares of Pharmacyclics (NASDAQ:PCYC) from $120.00 to $130.00 in a research note to investors on Friday, August 30th. They now have a “buy” rating on the stock. Finally, analysts at Credit Suisse raised their price target on shares of Pharmacyclics (NASDAQ:PCYC) from $90.00 to $121.00 in a research note to investors on Friday, August 2nd.
Five research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $120.25.
Pharmacyclics, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.